Media Releases» Go to news main
Dal researcher invents chemo delivery system that minimizes impact on healthy cells
A researcher at Dalhousie Medical School has developed a new way to deliver chemotherapy drugs. Using nanotechnology, the novel system releases chemo in cancerous cells only, leaving healthy cells alone. The work was recently published in Nature’s Scientific Reports.
Dr. Naga Puvvada, a postdoctoral fellow at Dalhousie Medicine New Brunswick (DMNB), created the drug delivery system. He worked in collaboration with DMNB’s Dr. Keith Brunt and researchers in the United States and India.
The research team designed a nano-particle that increases the amount of chemotherapy delivered to a tumour, and releases chemo only once inside tumour cells. This minimizes the impact on healthy tissue.
Only with the high level of acidity created by tumours does the nano-particle become activated – it then enters the cancerous cell and breaks open. As the nano-particle releases its chemotherapy, it undergoes a colour change, known as photo-switching. This photo-switching enables researchers to determine how much of the chemo has been released and can be used to identify the presence of tumours.
“What ‘s unique about our design is the potential clinical translatability of our fluorescent photo-switching, as it could help determine the amount of chemotherapy being released,” says Dr. Puvvada. “We still have some work to do before this is used in the clinic as the fluorescence is not currently picked up by MRIs or CTs. This is one of the next steps in our research.”
While the research was based on human breast cancer cells, it has the potential to be applied to any solid tumour.
“This new delivery system, while it is in its early stages, is promising for patient-tailored therapy in personalized medicine,” says Dr. Brunt, assistant professor in the Department of Pharmacology. “The potential to improve the quality of life for solid tumour cancer patients and their overall outcomes is within reach with this type of targeted, measurable treatment.”
The research was funded by the New Brunswick Health Research Foundation, the Reynolds Fellowship, and the Canadian Natural and Engineering Research Council.
For more information:
View Novel ZnO hollow-nanocarriers containing paclitaxel targeting folate-receptors in a malignant pH-microenvironment for effective monitoring and promoting breast tumor regression at nature.com/scientificreports.
Dr. Naga Puvvada (left), a postdoctoral fellow at Dalhousie Medicine New Brunswick (DMNB) and DMNB’s Dr. Keith Brunt (right). July 2015
Dr. Naga Puvvada (left) and Dr. Keith Brunt (right). July 2015
Dalhousie Medical School
1 (902) 222-1917
comments powered by Disqus
- Media opportunity: How are the world's reef sharks doing and what can be done to save them? Researchers will revisit marine protected areas in 26 nations to check their numbers and help design new conservation sites
- Media opportunity: Dalhousie University program will support Canadian physicians, residents and medical students with daily messages aimed at reducing stress, depression and burnout
- Media Opportunity: Dalhousie University congratulates faculty members Jerome Blais and Amy Brandon on Juno Award nominations
- Media opportunity: Dalhousie University social anthropologist explores the joyful reasons people are drawn to Mardi Gras and the sense of community it provides
- Media release: Innovative research presents deep dive on national fisheries health, finding bright spots along the way
- Media opportunity: Sleek, high‑resolution imaging probe gives physicians ability to see site of spinal nerve compression, greatly improving success of spine surgery
- Media opportunity: Majority of pediatric deaths in Nova Scotia involve males in rural areas, with car crashes causing most of the pre‑hospital traumas: research study
- Media release: Global study documents increasing trend in shark mortality despite finning regulations, identifies pathways to save threatened species